List of Tables
Table 1. Immunotherapy Drugs for Neuroblastoma Market Trends
Table 2. Immunotherapy Drugs for Neuroblastoma Market Drivers & Opportunity
Table 3. Immunotherapy Drugs for Neuroblastoma Market Challenges
Table 4. Immunotherapy Drugs for Neuroblastoma Market Restraints
Table 5. Global Immunotherapy Drugs for Neuroblastoma Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2019-2024)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Immunotherapy Drugs for Neuroblastoma Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Immunotherapy Drugs for Neuroblastoma Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Immunotherapy Drugs for Neuroblastoma Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Immunotherapy Drugs for Neuroblastoma Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Immunotherapy Drugs for Neuroblastoma
Table 13. Global Immunotherapy Drugs for Neuroblastoma Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Neuroblastoma as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Immunotherapy Drugs for Neuroblastoma Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Immunotherapy Drugs for Neuroblastoma Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Immunotherapy Drugs for Neuroblastoma Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Immunotherapy Drugs for Neuroblastoma Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Region (2019-2024) & (%)
Table 44. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Region (2025-2030) & (%)
Table 45. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Region (2019-2024) & (%)
Table 49. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Region (2025-2030) & (%)
Table 50. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Volume, (2025-2030) & (K Units)
Table 57. United Therapeutics Company Information
Table 58. United Therapeutics Introduction and Business Overview
Table 59. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 61. United Therapeutics Recent Development
Table 62. Y-mAbs Therapeutics Company Information
Table 63. Y-mAbs Therapeutics Introduction and Business Overview
Table 64. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 66. Y-mAbs Therapeutics Recent Development
Table 67. EUSA Pharma Company Information
Table 68. EUSA Pharma Introduction and Business Overview
Table 69. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 71. EUSA Pharma Recent Development
Table 72. ANI Pharmaceuticals Company Information
Table 73. ANI Pharmaceuticals Introduction and Business Overview
Table 74. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 76. ANI Pharmaceuticals Recent Development
Table 77. Baxter Healthcare Company Information
Table 78. Baxter Healthcare Introduction and Business Overview
Table 79. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 81. Baxter Healthcare Recent Development
Table 82. Ingenus Pharmaceuticals Company Information
Table 83. Ingenus Pharmaceuticals Introduction and Business Overview
Table 84. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 86. Ingenus Pharmaceuticals Recent Development
Table 87. Pfizer Company Information
Table 88. Pfizer Introduction and Business Overview
Table 89. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Pfizer Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 91. Pfizer Recent Development
Table 92. Hikma Pharmaceuticals Company Information
Table 93. Hikma Pharmaceuticals Introduction and Business Overview
Table 94. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 96. Hikma Pharmaceuticals Recent Development
Table 97. Teva Pharmaceuticals Company Information
Table 98. Teva Pharmaceuticals Introduction and Business Overview
Table 99. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Offerings
Table 101. Teva Pharmaceuticals Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Immunotherapy Drugs for Neuroblastoma Downstream Customers
Table 105. Immunotherapy Drugs for Neuroblastoma Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Immunotherapy Drugs for Neuroblastoma Product Picture
Figure 2. Global Immunotherapy Drugs for Neuroblastoma Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Immunotherapy Drugs for Neuroblastoma Sales Volume (2019-2030) & (K Units)
Figure 5. Global Immunotherapy Drugs for Neuroblastoma Sales Price (2019-2030) & (US$/Unit)
Figure 6. Immunotherapy Drugs for Neuroblastoma Report Years Considered
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Immunotherapy Drugs for Neuroblastoma Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Immunotherapy Drugs for Neuroblastoma Revenue in 2023
Figure 10. Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Dinutuximab Picture
Figure 12. Naxitamab Picture
Figure 13. Other Picture
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Immunotherapy Drugs for Neuroblastoma Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Immunotherapy Drugs for Neuroblastoma Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Clinic
Figure 21. Product Picture of Other
Figure 22. Global Immunotherapy Drugs for Neuroblastoma Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Immunotherapy Drugs for Neuroblastoma Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Immunotherapy Drugs for Neuroblastoma Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Immunotherapy Drugs for Neuroblastoma Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Immunotherapy Drugs for Neuroblastoma Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Immunotherapy Drugs for Neuroblastoma Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Immunotherapy Drugs for Neuroblastoma Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Immunotherapy Drugs for Neuroblastoma Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Immunotherapy Drugs for Neuroblastoma Sales Volume (%), (2019-2030)
Figure 39. United States Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 45. China Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 47. China Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 57. India Immunotherapy Drugs for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Immunotherapy Drugs for Neuroblastoma Sales Value by Type (%), 2023 VS 2030
Figure 59. India Immunotherapy Drugs for Neuroblastoma Sales Value by Application (%), 2023 VS 2030
Figure 60. Immunotherapy Drugs for Neuroblastoma Industrial Chain
Figure 61. Immunotherapy Drugs for Neuroblastoma Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
